Literature DB >> 26754004

Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients.

Antoine Kourilsky1, Guillaume Bertrand2, Renata Ursu1, Jennifer Doridam1,3, Ciprian Barlog1,3, Thierry Faillot4, Emmanuel Mandonnet5, Catherine Belin1, Christine Levy6, Antoine F Carpentier7,8.   

Abstract

Glioblastoma patients often require chronic administration of steroids due to peri-tumoral edema. Preliminary studies showed that treatment with Angiotensin-II Receptor Blockers (ARBs) for high blood pressure might be associated with reduced peri-tumoral edema. In this study, we aim to radiologically assess the effect of ARBs on peri-tumoral edema. We conducted a cross-sectional survey on patients with newly diagnosed GBM. Patients treated with ARBs for high blood pressure were paired to non ARB-treated patients based on similar age, tumor location and tumor size. Patients taking steroids at the time of pre-operative Magnetic Resonance Imaging were excluded from the study. In each pair of patients, we compared the volumes of peri-tumoral hyper T2-Fluid Attenuated Inversion Recovery (FLAIR) signal and the Apparent Diffusion Coefficient (ADC) in the same area. Eleven (11) ARB-treated patients were selected and paired to 11 non ARB-treated controls. Volumes of peri-tumoral hyper T2-FLAIR signal were significantly lower in the ARB-treated group than in the non ARB-treated group (p = 0.02). Additionally, peri-tumoral ADCs were also significantly lower in the treated group (p = 0.02), suggesting that the peri-tumoral area in this group had less edematous features. These results suggest that ARBs may reduce the volume of peri-tumoral hyper T2-FLAIR signal by decreasing edema.

Entities:  

Keywords:  ADC; Angiotensin receptor blockers; Edema; FLAIR; Glioblastoma

Mesh:

Substances:

Year:  2016        PMID: 26754004     DOI: 10.1007/s00415-015-8016-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

1.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

2.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Authors:  O V Volpert; W F Ward; M W Lingen; L Chesler; D B Solt; M D Johnson; A Molteni; P J Polverini; N P Bouck
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor.

Authors:  Hideto Sano; Kohei Hosokawa; Hiroyasu Kidoya; Nobuyuki Takakura
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-09-14       Impact factor: 8.311

4.  Steroid requirements during radiotherapy for malignant gliomas.

Authors:  Athina Marantidou; Christine Levy; Alyette Duquesne; Renata Ursu; Olivier Bailon; Irene Coman; Catherine Belin; Antoine F Carpentier
Journal:  J Neurooncol       Date:  2010-02-26       Impact factor: 4.130

5.  Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?

Authors:  Christina Hempen; Elisabeth Weiss; Clemens F Hess
Journal:  Support Care Cancer       Date:  2002-02-09       Impact factor: 3.603

6.  Angiotensin II AT1 receptor blockade decreases brain artery inflammation in a stress-prone rat strain.

Authors:  Hiromichi Ando; Miroslava Jezova; Jin Zhou; Juan M Saavedra
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

7.  Bradykinin potentiation by ACE inhibitors: a matter of metabolism.

Authors:  Beril Tom; Andreas Dendorfer; René de Vries; Pramod R Saxena; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

8.  Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells.

Authors:  Melissa A Fleegal-DeMotta; Shinya Doghu; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2009-01-07       Impact factor: 6.200

9.  Diffusion-weighted MR imaging of experimental brain tumors in rats.

Authors:  T Els; M Eis; M Hoehn-Berlage; K A Hossmann
Journal:  MAGMA       Date:  1995-03       Impact factor: 2.310

10.  Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma.

Authors:  O Arrieta; P Guevara; E Escobar; R García-Navarrete; B Pineda; J Sotelo
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

View more
  6 in total

1.  Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.

Authors:  Victor A Levin; James Chan; Meenal Datta; Jennie L Yee; Rakesh K Jain
Journal:  J Neurooncol       Date:  2017-06-19       Impact factor: 4.130

Review 2.  Renin angiotensin system and its role in biomarkers and treatment in gliomas.

Authors:  Alexander Perdomo-Pantoja; Sonia Iliana Mejía-Pérez; Liliana Gómez-Flores-Ramos; Montserrat Lara-Velazquez; Cordelia Orillac; Juan Luis Gómez-Amador; Talia Wegman-Ostrosky
Journal:  J Neurooncol       Date:  2018-02-16       Impact factor: 4.130

Review 3.  Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events.

Authors:  Matthias Pinter; Wilhelmus J Kwanten; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2018-04-02       Impact factor: 12.531

Review 4.  The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer.

Authors:  José A Carlos-Escalante; Marcela de Jesús-Sánchez; Alejandro Rivas-Castro; Pavel S Pichardo-Rojas; Claudia Arce; Talia Wegman-Ostrosky
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

Review 5.  Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.

Authors:  Matthias Pinter; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2017-10-04       Impact factor: 17.956

6.  Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma.

Authors:  Alexander Perdomo-Pantoja; Sonia Iliana Mejía-Pérez; Nancy Reynoso-Noverón; Liliana Gómez-Flores-Ramos; Ernesto Soto-Reyes; Thalía Estefania Sánchez-Correa; Lissania Guerra-Calderas; Clementina Castro-Hernandez; Silvia Vidal-Millán; José Sánchez-Corona; Lucia Taja-Chayeb; Olga Gutiérrez; Bernardo Cacho-Diaz; Rosa Maria Alvarez-Gomez; Juan Luis Gómez-Amador; Patricia Ostrosky-Wegman; Teresa Corona; Luis Alonso Herrera-Montalvo; Talia Wegman-Ostrosky
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.